Biomarkers in population studies: environmental mutagenesis and risk for cancer. Au WW, Ruchirawat M Rev Environ Health24p117-27(2009 Apr-Jun)

01 Apr 2009
0
0

Biomarkers in population studies: environmental mutagenesis and risk for cancer.
Au WW, Ruchirawat M
Rev Environ Health24p117-27(2009 Apr-Jun)

Tags

Share this

Related Posts

Chlorpyrifos promotes colorectal adenocarcinoma H508 cell growth through the activation of EGFR/ERK1/2 signaling pathway but not cholinergic pathway. Suriyo T, Tachachartvanich P, Visitnonthachai D, Watcharasit P, Satayavivad J. Toxicology. 2015; 338: 117-29.
02 Dec 2015
0

Chlorpyrifos promotes colorectal adenocarcinoma H508 cell growth through the activation of EGFR/ERK1/2 signaling pathway but not cholinergic pathway. Suriyo T, Tachachartvanich P, Visitnonthachai D, Watcharasit P, Satayavivad J. Toxicology. 2015; 338: 117-29.

Chlorpyrifos promotes colorectal adenocarcinoma H508 cell growth through the activation of EGFR/ERK1/2 signaling pathway but not cholinergic pathway. Suriyo T, Tachachartvanich P, Visitnonthachai D, Watcharasit P, Satayavivad J. Toxicology. 2015; 338: 117-29.
View More
An engineered cell line lacking OGG1 and MUTYH glycosylases implicates the accumulation of genomic 8-oxoguanine as the basis for paraquat mutagenicity. Tajai P, Fedeles BI, Suriyo T, Navasumrit P, Kanitwithayanun J, Essigmann JM, Satayavivad J. Free Radic Biol Med. 2018;116: 64-72.
20 Feb 2018
0

An engineered cell line lacking OGG1 and MUTYH glycosylases implicates the accumulation of genomic 8-oxoguanine as the basis for paraquat mutagenicity. Tajai P, Fedeles BI, Suriyo T, Navasumrit P, Kanitwithayanun J, Essigmann JM, Satayavivad J. Free Radic Biol Med. 2018;116: 64-72.

An engineered cell line lacking OGG1 and MUTYH glycosylases implicates the accumulation of genomic 8-oxoguanine as the basis for paraquat mutagenicity. Tajai P, Fedeles BI, Suriyo T, Navasumrit P, Kanitwithayanun J, Essigmann JM, Satayavivad J. Free Radic Biol Med. 2018;116: 64-72.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More